Single Use Bioreactor Design Patents: Leaders & Filing Trends 2026
Single Use Bioreactor Design Patents: Who Holds the Claims and Where They Thin Out
43.5% concentration at the top. The five largest assignees hold 157 of 361 records in scope — a tight cluster around wave-induced and stirred-tank designs, not a fragmented field. Filings ran from 39 in 2017 down to 5 by 2024 — an 82% decline across the 2021-2024 window. Treat 2025 and 2026 as incomplete: publication typically lags filing by around 18 months, so recent-year counts will rise as more records surface.
- 1EMD MILLIPORE CORP38
- 2GLOBAL LIFE SCIENCES SOLUTIONS USA LLC37
- 3PACIRA PHARMA INC28
- 4JUST EVOTEC BIOLOGICS INC27
- 5GENENTECH INC27
See the full single use bioreactor design analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on single use bioreactor design patents
Who holds the most patents in single use bioreactor design?
The assignee ranking covers 75 companies across 361 records, and the top-ranked assignee holds 38 records on its own. The five largest assignees combined hold 157 records, which is 43.5% of the full 361-record corpus, so filing activity is concentrated among a relatively small group rather than spread evenly. That said, the taper from first to tenth place is gradual rather than a cliff, meaning several firms are actively contesting the same design space.
Is single use bioreactor design still an active area for new patent filings?
Filings peaked at 39 in 2017 and had fallen to 5 by 2024, an 82% decline over the 2021-2024 window using complete-year data. That is a real slowdown, but publication typically lags filing by around 18 months, so 2025 and 2026 figures in this dataset are still incomplete and should not be read as the field going quiet. A clearer read on current activity will only be available once those recent years finish publishing.
What technology areas get the most patent claims in this field?
C12M, the IPC subclass covering bioreactors and enzyme apparatus, appears on 53.7% of the 361 records in scope, making it the dominant technology class by a wide margin. B01F mixing and stirring apparatus follows at 21.3%, and C12N microorganism and genetic engineering claims sit at 15.0%. Because a single record can carry multiple IPC classes, these percentages overlap rather than summing to a whole field.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Single Use Bioreactor Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.